AVONEX® (Interferon beta-1a) is a 166 amino acid glycoprotein.
AVONEX® (Interferon beta-1a) is indicated for the treatment of patients with relapsing forms of multiple sclerosis to slow the accumulation of physical disability and decrease the frequency of clinical exacerbations. Patients with multiple sclerosis in whom efficacy has been demonstrated include patients who have experienced a first clinical episode and have MRI features consistent with multiple sclerosis. Safety and efficacy in patients with chronic progressive multiple sclerosis have not been established.
Published Studies Related to Avonex (Interferon Beta-1A)
Comparing efficacy and side effects of a weekly intramuscular
biogeneric/biosimilar interferon beta-1a with Avonex in relapsing remitting
multiple sclerosis: a double blind randomized clinical trial. 
USA) and CinnoVex (CinnaGen, Iran)... CONCLUSION: CinnoVex can be used as a safe and effective alternative to Avonex in
Interferon, azathioprine and corticosteroids in multiple sclerosis: 6-year
follow-up of the ASA cohort. 
combined with low-dose azathioprine and prednisone in multiple sclerosis... CONCLUSION: The tested combined therapeutic regimen does not improve long-term
Interferon beta for secondary progressive multiple sclerosis. 
CONCLUSIONS: Well designed RCTs, evaluating a high number of patients
A novel PEGylated interferon beta-1a for multiple sclerosis: safety,
pharmacology, and biology. 
This study clinically evaluated a novel PEGylated form of interferon beta-1a
(PEG-IFN beta-1a), a potential first-line treatment for relapsing multiple
sclerosis, in healthy volunteers. Two randomized, blinded phase I studies were
conducted: a single-dose study (n = 60) comparing subcutaneous or intramuscular
PEG-IFN beta-1a (63, 125, or 188 µg) with intramuscular unmodified IFN beta-1a 30
µg and a multiple-dose study (n = 69) comparing subcutaneous PEG-IFN beta-1a
dosed once every 2 or 4 weeks with placebo...
Efficacy of vitamin D(3) as add-on therapy in patients with relapsing-remitting multiple sclerosis receiving subcutaneous interferon beta-1a: A Phase II, multicenter, double-blind, randomized, placebo-controlled trial. [2011.12.15]
Recent studies have demonstrated the immunomodulatory properties of vitamin D, and vitamin D deficiency may be a risk factor for the development of MS. The risk of developing MS has, in fact, been associated with rising latitudes, past exposure to sun and serum vitamin D status...
Clinical Trials Related to Avonex (Interferon Beta-1A)
Study to Determine if Avonex and Rebif Work Comparably Well in Subjects With Relapsing Multiple Sclerosis [Completed]
The purpose of this study is to find out if weekly Avonex works as well as three times a week
Rebif in subjects with relapsing multiple sclerosis.
Avonex (Interferon-Beta-1a) and Avonex Plus Methylprednisolone for the Treatment of Relapsing-Remitting MS [Active, not recruiting]
The primary objective of this study is to determine whether combination treatment (adding
methylprednisolone to Avonex) reduces progression of disability over 4 years compared to
Avonex alone. The study will also investigate whether combination therapy has any impact on
the incidence of relapse and brain atrophy as measured by MRI.
Rebif New Formulation (RNF) Quality of Life Study [Active, not recruiting]
To evaluate the impact on Quality of Life, tolerability, treatment satisfaction, and
injection site redness Rebif treated subjects with relapsing forms of MS who transition to a
new formulation of Rebif.
Transition to Rebif New Formulation [Active, not recruiting]
To assess patient satisfaction with respect to the incidence of flu-like symptoms in patients
with multiple sclerosis transitioned from current Rebif (subcutaneously injected interferon
beta-1a, 44mcg three-times-weekly) to the new formulation of Rebif while receiving ibuprofen
either prophylactically or only when necessary (PRN) after the occurance of flu-like
Avonex Safety and Tolerability in Chinese Subjects With Relapsing Multiple Sclerosis (MS) [Recruiting]
The study is designed to determine the effect of weekly intramuscular (IM) administration of
30 mcg Avonex (interferon beta 1a) on safety parameters and gadolinium (Gd) enhanced and
T2-weighted cranial magnetic resonance imaging (MRI) lesions in Chinese patients with
clinically diagnosed (using revised McDonald criteria) relapsing multiple sclerosis (MS).
Reports of Suspected Avonex (Interferon Beta-1A) Side Effects
Influenza Like Illness (821),
Multiple Sclerosis Relapse (734),
Gait Disturbance (517),
Memory Impairment (355),
Injection Site Pain (335),
Injection Site Haemorrhage (316), more >>
Page last updated: 2013-02-10